Losartan Does Not Prevent Vestibular Schwannoma Growth Or Related Hearing Loss During Observation
Journal of Neurological Surgery Part B: Skull Base · 01.02.2024 · 85 (S 01 S 01) · S1-S398
DOI: 10.1055/s-0044-1779958 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurological Surgery Part B: Skull Base, erschienen am 01.02.2024. Verfasst von Benjamin D. Lovin und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Objectives
Previous research in a rodent model showed that losartan prevents tumor-induced hearing loss. As such, this study sought to review and evaluate the potential impact of losartan on vestibular schwannoma (VS) growth and related hearing loss during observation.
Methods
Retrospective cohort study was performed on sporadic VS patients undergoing initial observation who had at least two magnetic resonance imaging (MRI) and audiologic studies. Patients were stratified by losartan use during the observation period. Primary endpoints were VS growth and audiologic changes. Tumor growth was defined as at least 2-mm increase in diameter between the first and last MRI. Audiologic changes were evaluated quantitatively through pure tone average (PTA) and word recognition score (WRS), which were normalized for age-related hearing loss based on the decrement in the contralateral ear, and qualitatively by evaluating progression to non-serviceable hearing loss. Non-serviceable hearing was defined as AAO-HNS class C or D hearing. Survival free of tumor growth and non-serviceable hearing loss were evaluated between groups.
Results
Total of 79 patients were included, of which 33% were taking losartan. The mean patient age was 58.1 years and mean length of radiographic observation was 44.5 months. Tumor growth was seen in 41% of all patients. More patients in the losartan group demonstrated tumor growth, but this was not statistically significant ( p = 0.329). Furthermore, logistic regression analysis did not demonstrate a statistically significant difference between groups in the odds of VS growth (OR = 1.79, 95% CI = 0.69–4.64, p = 0.231). Finally, survival analysis did not demonstrate a statistically significant difference in time to VS growth between groups (hazard ratio [HR] = 1.38, 95% confidence interval [CI] = 0.70–2.70, log-rank test p = 0.346; [ Fig. 1 ]). Audiologically, the mean lengths of quantitative and qualitative audiologic observation were 40.8 and 43.2 months, respectively. The total mean decrement in normalized PTA and WRS were 8.0 dB and 14.8%, respectively, and 26% of all patients developed non-serviceable hearing loss. Losartan users had slightly smaller decrements in normalized PTA and WRS and lower rates of developing non-serviceable hearing loss compared to non-losartan users, but the differences were not significant ( p = 0.908, 0.757, and 0.734, respectively). Furthermore, logistic regression analysis did not demonstrate a statistically significant difference between groups in the odds of developing non-serviceable hearing (OR = 0.59, 95% CI = 0.14–2.47, p = 0.468). Finally, survival analysis did not demonstrate a statistically significant difference in time to developing non-serviceable hearing between losartan and non-losartan groups (HR = 1.71, 95% CI = 0.56–5.21, log-rank test p = 0.337; [ Fig. 2 ]).
Conclusions
Losartan does not appear to reduce the odds of VS growth or hearing loss during observation. A randomized trial would be ideal to further identify the true effect on growth and hearing. Fig. 1 Kaplan–Meier curve of survival free of vestibular schwannoma growth for losartan and non-losartan groups. Number at risk denotes the remaining patients in each group who had not demonstrated non-serviceable hearing by the according timepoint. Fig. 2 Kaplan–Meier curve of survival free of developing non-serviceable hearing for losartan and non-losartan groups. Number at risk denotes the remaining patients in each group who had not demonstrated non-serviceable hearing by the according timepoint. Publication History Article published online: 05 February 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Lovin, B. D., Nader, M., Qing, Y., Hernandez, M., Raza, S., DeMonte, F., & Gidley, P. W. (2024). Losartan Does Not Prevent Vestibular Schwannoma Growth Or Related Hearing Loss During Observation. Journal of Neurological Surgery Part B: Skull Base, 85(S 01 S 01), S1-S398. https://doi.org/10.1055/s-0044-1779958
Vancouver
Lovin BD, Nader M, Qing Y, Hernandez M, Raza S, DeMonte F, et al. Losartan Does Not Prevent Vestibular Schwannoma Growth Or Related Hearing Loss During Observation. Journal of Neurological Surgery Part B: Skull Base. 2024;85(S 01 S 01):S1-S398. doi:10.1055/s-0044-1779958
BibTeX
@article{Lovin2024,
author = {Lovin, Benjamin D. and Nader, Marc-Elie and Qing, Yun and Hernandez, Mike and Raza, Shaan and DeMonte, Franco and Gidley, Paul W.},
title = {Losartan Does Not Prevent Vestibular Schwannoma Growth Or Related Hearing Loss During Observation},
journal = {Journal of Neurological Surgery Part B: Skull Base},
year = {2024},
volume = {85},
number = {S 01 S 01},
pages = {S1--S398},
doi = {10.1055/s-0044-1779958}
}
EUVIMED